Cells of the synovium in rheumatoid arthritis. Macrophages

  • Raimund W Kinne1Email author,

    Affiliated with

    • Bruno Stuhlmüller2 and

      Affiliated with

      • Gerd-R Burmester2

        Affiliated with

        Arthritis Research & Therapy20079:224

        DOI: 10.1186/ar2333

        Published: 21 December 2007


        The multitude and abundance of macrophage-derived mediators in rheumatoid arthritis and their paracrine/autocrine effects identify macrophages as local and systemic amplifiers of disease. Although uncovering the etiology of rheumatoid arthritis remains the ultimate means to silence the pathogenetic process, efforts in understanding how activated macrophages influence disease have led to optimization strategies to selectively target macrophages by agents tailored to specific features of macrophage activation. This approach has two advantages: (a) striking the cell population that mediates/amplifies most of the irreversible tissue destruction and (b) sparing other cells that have no (or only marginal) effects on joint damage.


        Macrophages (Mφ) are of central importance in rheumatoid arthritis (RA) due to their prominent numbers in the inflamed synovial membrane and at the cartilage-pannus junction, their clear activation status [1, 2] (see Table 1 for overview), and their response to successful anti-rheumatic treatment [3]. Although Mφ probably do not occupy a causal pathogenetic position in RA (except for their potential antigen-presenting capacity), they possess broad pro-inflammatory, destructive, and remodelling potential and contribute considerably to inflammation and joint destruction in acute and chronic RA. Also, activation of this lineage extends to circulating monocytes and other cells of the mononuclear phagocyte system (MPS), including bone marrow precursors of the myelomonocytic lineage and osteoclasts [2, 4, 5].
        Table 1

        Activation status of synovial macrophages and/or circulating monocytes in rheumatoid arthritis

        Class of overexpressed molecules


        Known or potential function

        Class II major histocompatibility complex (overexpressed on Mφ)


        Presentation of antigens relevant to disease initiation or severity [93] (Stuhlmuller B, et al., unpublished data) (reviewed in [2])

        Cytokines and growth factors

        For example, TNF-α, IL-1, IL-6, IL-10, IL-13, IL-15, IL-18, migration inhibitory factor, granulocyte macrophage colony-stimulating factor, and thrombospondin-1

        Mediation and regulation of local and systemic inflammation and tissue remodelling (reviewed in [2,24,39,52])

        Chemokines and chemoattractants

        For example, IL-8, macrophage inflammatory protein-1, monocyte chemoattractant protein-1, and CXCL13

        Mediation and regulation of monocyte migration Stimulation of angiogenesis (reviewed in [69])

        Metalloproteases (MMPs)

        MMP-9 and MMP-12

        Tissue degradation and post-injury tissue remodelling [94,95]

        Tissue inhibitors of MMP (TIMPs)


        Attempt to control excessive tissue destruction [96]

        Acute-phase reactants

        For example, C-reactive protein and A-SAA (serum amyloid A)

        Integrated hormone-like activation of hepatocytes by synovial Mφ and fibroblasts (mostly via IL-6) [97] (reviewed in [2])

        Other molecules


        Produced by interferon-gamma-stimulated monocytes/Mφ

        Induces/enhances cytotoxicity and apoptosis Acts as antioxidant [98,99]



        Produced by TNF-α-stimulated Mφ

        Regulates nuclear factor-kappa-B and caspase-1 activation [100]

        IL, interleukin; Mφ, macrophages; TNF-α, tumor necrosis factor-alpha. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55–75 [2].

        Thus, before a causal factor for RA is known, monocytes/Mφ remain an attractive research focus for the following reasons: (a) the radiological progression of joint destruction correlates with the degree of synovial Mφ infiltration [1], (b) the therapeutic efficacy of conventional anti-rheumatic therapy coincides with downregulation of MPS functions [6], (c) therapies directed at cytokines made predominantly by Mφ are effective in RA [7], (d) conventional or experimental drugs can be selectively targeted to Mφ or their different subcellular compartments (for example, [2, 8]), (e) differential activation of intracellular signal transduction pathways underlies different Mφ effector functions [9], and (f) more specific inhibitors of key metabolic enzymes or particular signal transduction pathways may become available as selective targets of anti-rheumatic therapy [9, 10]. In addition, the amplifying role of Mφ in RA has emerged so clearly that the effects of anti-rheumatic therapy (whether specific or conventional) on monocytes/Mφ may become an objective readout of the effectiveness of treatment [1113] (Stuhlmuller B, Hernandez MM, Haeupl T, Kuban RJ, Gruetzkau A, Voss JW, Salfeld J, Kinne RW, Burmester GR, unpublished data).

        Differentiation and activation of the mononuclear phagocyte system in rheumatoid arthritis

        Cells of the myelomonocytic lineage differentiate into several cell types critically involved in disease (that is, monocytes/Mφ, osteoclasts, and dendritic cells) (Figure 1a). Due to their marked plasticity, these pathways can be influenced by an excess/imbalance of cytokines or growth factors, resulting in altered differentiation/maturation (Figure 1b). In RA, such imbalances clearly occur in inflamed joints, peripheral blood, and bone marrow (Table 2 and Figure 1b).
        Figure 1

        Physiological/pathological differentiation of the mononuclear phagocyte system in rheumatoid arthritis (RA). (a) Physiological differentiation of the mononuclear phagocyte system (MPS) (steady-state cytokine and growth factor milieu). In the human MPS, monocytes (M) differentiate from a CD34+ stem cell via an intermediate step of monoblasts. Monocytes leave the bone marrow and remain in circulation for approximately 3 days. Upon entering various tissues, they differentiate into different types of resident macrophages (Mφ), including synovial macrophages. It is believed that these mature cells do not recirculate, surviving for several months in their respective tissues until they senesce and die. Some circulating monocytes retain the potential for differentiating into dendritic cells and osteoclasts (asterisk in the insert). The steady-state myeloid differentiation involves many factors, including granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha (TNF-α), which are produced by resident bone marrow macrophages (reviewed in [2]). (b) Increased plasticity of myeloid differentiation and its possible role in RA (augmented cytokine and growth factor milieu). Human bone marrow intermediate cells can differentiate into macrophages or dendritic cells in the presence of c-kit ligand, GM-CSF, and TNF-α. TNF-α, in turn, inhibits the differentiation of monocytes into macrophages in vitro and, together with GM-CSF, directs the differentiation of precursor cells into dendritic cells, another important arm of the accessory cell system. Also, either IL-11 or vitamin D3 and dexamethasone induce the differentiation of bone marrow cells or mature macrophages into osteoclasts, cells involved in the destruction of subchondral bone in RA. Osteoclasts and dendritic cells can also be derived from circulating monocytes upon stimulation with macrophage colony-stimulating factor (M-CSF) or IL-4 plus GM-CSF. This plasticity, and its dependence on growth factors or cytokines that are clearly elevated in peripheral blood and bone marrow of patients with RA, may explain some differentiation anomalies in the disease and also the efficacy of some anti-rheumatic drugs. Non-specific enhancement of monocyte maturation and tissue egression, in turn, are consistent with the known alterations in inflammation (reviewed in [2]). The differentiation paths potentially relevant to RA are indicated by bold arrows. The jagged arrows represent possible sites of cell activation. CFU-GM, colony-forming units-granulocyte macrophage; CFU-M, colony-forming units-macrophage; MNC, mononuclear cells; PM(N), polymorphonuclear leukocytes. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55–75 [2].

        Table 2

        Potential sites of myelomonocytic activation in rheumatoid arthritis and corresponding steps of macrophage intermediate or terminal (trans) differentiation



        Differentiation step

        Joint or juxta-articular

        Synovial membrane

        • Recently immigrated monocytes


        • Mφ (M1/M2? [64]; resident/inflammatory? [13])


        • Dendritic cells


        Cartilage-pannus junction


        Subchondral bone



        Vascular endothelium



        Peripheral blood

        Circulating monocytes


        Bone marrow

        • Myelomonocytic precursors


        • Endothelial cells


        Subendothelial space

        Mφ/foam cells/pericytes


        Rheumatoid nodules

        Epitheloid cells and multinucleated giant cells


        Lung interstitial space

        Alveolar Mφ

        Mφ, macrophages. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55–75 [2].

        Cells of the MPS show clear signs of activation, not only in synovial and juxta-articular compartments such as the synovial membrane or the cartilage-pannus and bone-pannus junctions (including the subchondral bone), but also in extra-articular compartments (for example, peripheral blood and subendothelial space, the latter of which is the site of foam cell formation and development of atherosclerotic plaques in RA) (Table 2). This activation underlines the systemic inflammatory character of RA and may contribute to the occurrence of cardiovascular events and its increased mortality (reviewed in [2, 14, 15]).

        Biological functions of monocytes/macrophages and their role in rheumatoid arthritis

        The monocyte/Mφ system represents an integral part of the natural immune system and participates in the first-line response against infectious agents. Another crucial contribution to the body's homeostasis is the scavenging function of any debris generated by physiological or pathological processes. Thus, monocytes/Mφ possess multiple and powerful biological functions that may greatly affect onset and development of chronic inflammatory diseases like RA (see overview in Table 3) (reviewed in [16]).
        Table 3

        Monocyte/macrophage functions and their (potential) role in rheumatoid arthritis



        (Potential) role in rheumatoid arthritis

        Clearance of immune complexes

        Binding of immunoglobulins to Fc receptors (Fc-γ-R I, IIA, IIB, and IIIA)

        Potential clearance of rheumatoid factor but further activation of monocytes/Mφ


        Opsonization of complexes by complement, leading to binding to Mφ complement receptors and further cell activation [101,102] (reviewed in [2,103])


        Notably, inhibition of monocyte activation by Fc-γ-R IIB [102]

        Complement activation

        Binding of complement factors to complement receptors 1 (CD35), 3 (CD11b), and 5a (CD88)

        Recognition of activated complement (soluble phase or on immunoglobulin G-immune complexes)


        Promotion of phagocytosis and activation of monocytes/Mφ [103]

        Phagocytosis of particulate antigens

        Conventional (Fc-mediated) → lysosomal degradation and MHC-II antigen processing

        Scavenging of debris but potential import of arthritogenic molecules [103]


        Antigen presentation and activation of CD4+ and CD8+ T cells, possibly relevant to disease initiation or perpetuation (spreading of autoimmunity) (reviewed in [2])


        Coiling phagocytosis → lysosomal degradation and MHC-I antigen processing

        Involved in phagocytosis of Borrelia burgdorferi, active agent of Lyme arthritis (reviewed in [2])

        Clearance of intracellular pathogens and apoptotic cells

        Removal of pathogens and recognition of apoptotic cells via exposed intracellular membrane components

        Induction of Mφ-derived cytokines by bacterial toxins or superantigens [26,28,103]


        Modulation of Mφ responses by mycobacterial lipoarabinomannan [104,105] or Toll-like receptors [29,106]


        Persistence of obligate/facultative intracellular pathogens with arthritogenic potential [107,108]

        Antigen processing and presentation

        Enzymatic degradation of antigens and binding of antigenic peptides to MHC molecules and transport to the cell surface

        Important cognate functions upon antigen recognition via presentation of antigen on MHC-II molecules [109] and expression of membrane second signal molecules adjacent to T cells (reviewed in [2])

        Chemotaxis and angiogenesis

        Attraction of other inflammatory cells and induction of neo-vascularization

        Positive feedback between Mφ-derived cytokines and chemotactic factors (for example, IL-8 and monocyte chemoattractant protein-1) Promotion of angiogenesis by IL-8 and soluble forms of adhesion molecules (for example, vascular cell adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1) [69]

        Wound healing

        Remodelling of tissue via interaction with fibroblasts

        Sustained monocyte recruitment at wound injury sites via monocyte chemoattractant macrophage inflammatory protein-1α Phagocytosis of matrix debris and endogenous production of IL-1, TNF-α, and so on as well as post-injury tissue remodelling (reviewed in [2])

        Lipid metabolism

        Mφ synthesis of prostaglandins (PGs) E2 and I2 Expression of scavenger receptor A (uptake of oxidized low-density lipoprotein)

        Pro-inflammatory activity of PGE2 and PGI2 and leukotrienes in rheumatoid arthritis, but also autocrine negative feedback through peroxisome proliferator-activated receptors α and γ (reviewed in [2]) Fish-based diets are associated with clinical improvement of human and experimental arthritis (reviewed in [2])


        Modulation of T cell-contact-induced production of IL-1β and TNF-α in Mφ by apolipoprotein A-I [110]

        IL, interleukin; Mφ, macrophage(s); MHC, major histocompatibility complex; TNF-α, tumor necrosis factor-alpha. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55–75 [2].

        Stimulation/regulation of monocyte/macrophage activation in rheumatoid arthritis

        The role of monocytes/Mφ in RA is conceivably the integrated result of stimulatory, effector, dually active, and autoregulatory mediators/mechanisms. At the tissue level, the scenario is characterized by the influx of pre-activated monocytes, their maturation into resident Mφ, their full activation, and their interaction with other synovial cells. The complexity of the interaction is the result of paracrine activation mechanisms generated via sheer cell-cell contact as well as of numerous autocrine mechanisms – nearly any soluble mediator shows abnormalities. A simplified scheme of this integrated system and the currently known mediators is provided in Figure 2. For ease of presentation, the parts are organized as incoming stimuli (both paracrine and soluble) (column a) and effector molecules (column b), although autocrine loops are also relevant (as discussed below).
        Figure 2

        Paracrine, juxtacrine, and autocrine stimuli (column a) and effector molecules (column b) of macrophage (Mφ) activation in rheumatoid arthritis. Most of the regulatory products of activated macrophages act on macrophages themselves, creating autocrine regulatory loops whose dysregulation possibly promotes disease severity and chronicity. The jagged arrow in the T cell indicates the necessity of pre-activating T cells for effective juxtacrine stimulation of macrophages. AP-1, activation protein; EC, endothelial cells; FB, fibroblasts; ICAM, intracellular adhesion molecule; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; LFA-3, lymphocyte function-associated antigen-3; MIF, migration inhibitory factor; mTNF-α, mouse tumor necrosis factor-alpha; NF-κB, nuclear factor-kappa-B; NK, natural killer cells; sTNF-R, soluble tumor necrosis factor receptor; TGF-β, transforming growth factor-beta; TNF-α, tumor necrosis factor-alpha; VCAM-1, vascular cell adhesion molecule-1. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55–75 [2].

        Cell-cell interaction

        A significant part of Mφ effector responses is mediated by cell contact-dependent signalling with different inflammatory or mesenchymal cells (as exemplified in the lower left quadrant of Figure 2).

        Fibroblast-macrophage interaction

        Because of the prominent numbers of Mφ and fibroblasts and their activated status in RA synovial tissue, the interaction of these cells is critical for the resulting inflammation and tissue damage. Indeed, the mere contact of these cells elicits the production of interleukin (IL)-6, granulocyte macrophage colony-stimulating factor (GM-CSF), and IL-8. The cytokine output can be enhanced or down-modulated not only by addition of pro-inflammatory or regulatory cytokines (for example, IL-4, IL-10, IL-13, or IL-1 receptor antagonist [IL-1RA]), but also by neutralization of the CD14 molecule [17]. Also, in vitro, significant cartilage degradation occurs in co-cultures of mouse fibroblasts and Mφ, a response markedly exceeding that observed with each culture alone (reviewed in [2]). Furthermore, purified human synovial fibroblasts co-cultured with myelomonocytic cells induce cartilage degradation in vitro, but with a strong contribution of soluble IL-1 and tumor necrosis factor (TNF)-α [18].

        T cell-macrophage interaction

        Accessory, inflammatory, effector, and inhibitory Mφ functions can be stimulated by fixed T cells or their plasma membranes if T cells are pre-activated and express activation surface molecules. In response to such interaction, monocytes produce metalloprotease (MMP), IL-1α, and IL-1β [19, 20]. Also, T cells pre-stimulated in an antigen-mimicking fashion stimulate TNF-α and IL-10 production once in contact with monocytes [20]. Conversely, fixed T cells stimulated in an antigen-independent fashion (that is, with IL-15, IL-2, or a combination of IL-6 and TNF-α, the so-called Tck cells) induce monocyte production of TNF-α but not the anti-inflammatory IL-10 [20, 21]. These findings suggest that early RA may reflect antigen-specific T cell-Mφ interactions [22]. Conversely, chronic RA may be associated with antigen-independent interactions dominated by an exuberant cytokine milieu and Tck cells. This may also explain the relative paucity of IL-10 in the synovial membrane in chronic RA, as discussed below.

        Several ligand pairs on T cells and monocytes/Mφ have been implicated in this interaction [20], although the importance of individual ligand pairs, as well as the influence of soluble mediators, remains unclear. Interestingly, T cells isolated from RA synovial tissue show phenotypical and functional features similar to Tck cells and the above-mentioned signal transduction pathways differentially contribute to the induction of TNF-α and IL-10 production in monocytes/Mφ by co-culture with Tck cells. If applicable in vivo in RA, this would allow selective therapeutic targeting of pro-inflammatory TNF-α and sparing of anti-inflammatory IL-10.

        Interaction of macrophages with endothelial cells and natural killer cells

        The interaction between monocytes and endothelial cells in RA (Figure 2), critical for the sustained influx of activated monocytes in the synovial membrane, relies on the altered expression of integrin/selectin pairs on the surface of the two cell types (reviewed in [2]). Because the synovial cytokine milieu (including the Mφ-derived TNF-α) upregulates the expression of these ligand pairs, a self-perpetuating cycle ensues by which sustained Mφ-derived mechanisms lead to further influx and activation of circulating monocytes. Upon cell contact, monokine-activated CD56bright natural killer cells induce monocytes to the production of TNF-α, thus representing another possible reciprocal loop of activation in RA [23].

        Soluble stimuli

        Cytokine stimuli with pro-inflammatory effects on macrophages

        Numerous cytokines with known or potential stimulatory activity on monocytes/Mφ have been identified, as schematically shown in the upper left quadrant of Figure 2. A systematic list of these stimuli and their known or potential functions is provided in Table 4. Some of these mediators are produced by monocytes/Mφ themselves and therefore activate Mφ in an autocrine fashion, as also exemplified in Table 4. T-cell cytokines acting on Mφ (for example, IL-17) have been comprehensively reviewed elsewhere [24, 25].
        Table 4

        Overview of pro-inflammatory interleukins relevant to macrophage (dys)function in rheumatoid arthritis






        Main pathogenetic features






        Predominantly produced by Mφ


        Critical mediator of tissue damage


        Possesses autocrine features [43,51-53]






        Predominantly produced by Mφ


        Critical pleiotropic mediator of disease


        Possesses autocrine features [59-61]






        Produced by endothelial cells


        Important Th2-inducing component in allergy/autoimmunity


        Signals via IL-1 receptor-related protein (ST2)


        Nuclear factor with transcriptional repressor properties (≈ nuclear factor from high endothelial venules) [111-113]

        IL-18 inducible





        Pro-inflammatory effects on both myeloid and non-myeloid cells [114,115]






        Elevated in RA, although a relative paucity is also possible [116,117]


        Induces osteoclastic bone loss in mice [118]






        Produced by Mφ


        Important autocrine mediator of disease processes [21,56-58]






        Only IL-21R is expressed by synovial Mφ and fibroblasts [119]






        Predominantly produced by fibroblasts under the influence of Mφ


        Most strikingly elevated cytokine in acute RA, with phase-dependent differential effects [17,75,76] (reviewed in [2,77])






        Induces experimental dermatitis [120]






        Stimulates proteoglycan resorption in cartilage [121]


        Oncostatin M




        Recruits leukocytes to inflammatory sites and stimulates production of metalloprotease (MMP) and tissue inhibitor of MMP [121]

        IFN type I/IL-10





        Involved in both Th1 and Th2 inflammatory disorders [122,123]


        Possesses autocrine features [124,125]






        Overexpressed in psoriasis


        Possesses autocrine features [122]






        Relevant to innate immunity and acute-phase response [126]






        Possible antagonism with regulatory IL-10 [127]






        Polymorphism possibly contributes to RA sex-bias susceptibility [128]


        IL-28, IL-29




        Involved in microbial recognition by upregulation of Toll-like receptors


        Possesses autocrine features [30,129,130]






        Predominantly produced by synovial Mφ and dendritic cells


        Promotes Th1 responses (reviewed in [62])






        Predominantly produced by synovial Mφ and dendritic cells


        Shares p40 subunit with IL-12 and possibly antagonizes IL-12 [63] (reviewed in [62])






        Produced by Mφ and its neutralization has anti-arthritic effects


        Possesses autocrine features [66]


        Pro-inflammatory role [67]






        Th0-Th1 lymphokine with pleiotropic, amplifying effects on Mφ arthritis (reviewed in [24,25])

        IFN, interferon; LIF, leukemia inhibitory factor; Mφ, macrophages; RA, rheumatoid arthritis. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55–75 [2].

        Bacterial/viral components and Toll-like receptors

        The ability of bacterial toxins or superantigens to initiate the secretion of Mφ-derived cytokines is relevant in view of a possible microorganism etiology of RA and in view of side effects of anti-TNF-α therapy, particularly mycobacterial infections [26, 27]. Lipopolysaccharide (LPS), for example, binds to Mφ through the CD14/LPS-binding protein receptor complex and, in vitro, stimulates the production of IL-1β, TNF-α, and macrophage inflammatory protein-1α. Staphylococcal enterotoxin B (SEB), a potent Mφ activator, enhances arthritis in MRL-lpr/lpr mice. Anti-TNF-α therapy, in this case, reverses both the severe wasting effects of SEB and the incidence of arthritis, indicating that TNF-α is central in this system. Finally, the staphylococcal enterotoxin A increases the expression of the Toll-like receptor (TLR)-4 in human monocytes by ligation of major histocompatibility complex-II, with subsequent enhancement of pro-inflammatory cytokines by known TLR-4 ligands (for example, LPS [28]).

        TLRs are part of the recently discovered cellular pattern-recognition receptors (PPRs) involved in first-line defense of the innate immune system against microbial infections. In addition to bacterial or viral components, some PPRs recognize host-derived molecules, such as the glycoprotein gp96, nucleic acids, hyaluronic acid oligosaccharides, heparan sulfate, fibronectin fragments, and surfactant protein A (reviewed in [29]). In RA, notably, functional TLR-2 and TLR-4 are expressed on CD16+ synovial Mφ, peripheral blood mononuclear cells, and synovial fibroblasts [30]. Also, their expression can be upregulated by cytokines present in the inflamed RA joint (for example, IL-1β, TNF-α, macrophage colony-stimulating factor, and IL-10); this suggests that activation of synovial cells via TLRs may contribute to disease processes [29], as supported by findings in experimental arthritis [31]. On the other hand, the chronic polyarthritis observed in mice with deletion of the DNase II gene, whose Mφ are incapable of degrading mammalian DNA, appears to occur independently of the nucleic acid-specific TLR-9 [32].


        Females are affected by RA at a ratio of approximately 3:1 compared with males and experience clinical fluctuations during the menstrual cycle and pregnancy, indicating a major modulating role for sex hormones. Due to their expression of sex-hormone receptors and their cytokine response upon exposure to estrogens, monocytes/Mφ are strongly involved in hormone modulation of RA [33]. Indeed, physiological levels of estrogens stimulate RA Mφ to the production of the pro-inflammatory cytokine IL-1, whereas higher levels inhibit IL-1 production, conceivably mimicking the clinical improvement during pregnancy. Interestingly, selective estrogen receptor ligands inhibiting nuclear factor (NF)-κB transcriptional activity (but lacking estrogenic activity) can markedly inhibit joint swelling and destruction in experimental arthritis [34].

        Cytokine stimuli with regulatory effects on macrophages

        In addition to pro-inflammatory cytokines, several cytokines that regulate monocyte/Mφ function in RA have been described (summarized in the upper left quadrant of Figure 2). A systematic list of these cytokines is provided in Table 5. Interestingly, some of these molecules are produced by Mφ themselves (most notably, IL-10), so that autocrine regulation may also play a prominent role during the different clinical phases of RA. Other regulatory cytokines derive from other cell types present in the inflamed synovial membrane: T cells (for example, IL-4 and IL-13) or stromal cells (for example, IL-11). For these molecules, the reader is referred to recent publications or comprehensive reviews [25, 35, 36].
        Table 5

        Overview of anti-inflammatory cytokines relevant to macrophage (dys)function in rheumatoid arthritis





        Main pathogenetic features





        Produced by differentiated Mφ and upregulated by pro-inflammatory mediators, including IL-1 itself or granulocyte macrophage colony-stimulating factor

        Autocrine contribution to the termination of inflammatory reactions [54,55] (reviewed in [53,56])





        Strong regulator of Mφ functions but virtually absent in synovial tissue [73,131-133]





        Produced by synovial Mφ

        Strong regulator of Mφ functions but relatively deficient in RA

        Possesses autocrine features [73,74]





        Regulator of Mφ functions in a paracrine regulatory loop with synovial fibroblasts [36,134]





        Selective regulator of Mφ functions

        Improves experimental arthritis (reviewed in [2,91])





        Known as an anti-inflammatory molecule [135,136], IL-16 also has pro-inflammatory properties (that is, correlates with metalloprotease-3 levels, progression of joint destruction, and levels of other pro-inflammatory cytokines) [137,138].





        Clear anti-inflammatory and anti-destructive effects in experimental arthritides

        Therapy attempts in human RA thus far have been unsuccessful [149].





        Produced by Mφ [78-80]


        Main regulator of connective tissue remodelling


        Potent inducer of hyaluronan synthase 1


        Induces synovial inflammation (reviewed in [80]) but also suppresses acute and chronic arthritis [81,82]


        Induces inflammation and cartilage degradation in a rabbit model [140]


        Possesses autocrine features


        MMP can affect TGF-β via shedding of latent TGF-β attached to decorin (disease-enhancing loop).

        IFN-β, interferon-beta; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; Mφ, macrophage(s); RA, rheumatoid arthritis; TGF-β, transforming growth factor-beta. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55–75 [2].

        Monocyte/macrophage effector molecules in rheumatoid arthritis

        Monocyte/macrophage effector molecules with proinflammatory effects in rheumatoid arthritis

        Mφ produce a number of pro-inflammatory cytokines, as schematically shown in the upper right quadrant of Figure 2. A systematic list of the pro-inflammatory ILs is provided in Table 4.

        Tumor necrosis factor-alpha

        TNF-α is a pleiotropic cytokine that increases the expression of cytokines, adhesion molecules, prostaglandin E2, collage-nase, and collagen by synovial cells. TNF-α exists in membrane-bound and soluble forms, both acting as pro-inflammatory mediators. Transmembrane TNF-α is involved in local, cell contact-mediated processes and appears to be the prime stimulator of the R75 receptor [37]. Interestingly, the transgenic expression of this form is alone sufficient to induce chronic arthritis [38]; likewise, a mutant membrane TNF-α, which uses both R55 and R75 receptors, can cause arthritis. Conversely, the soluble form of TNF-α, shed via MMP cleavage from the membrane-bound form, primarily stimulates the R55 receptor, acting transiently and at a distance [37].

        In RA, TNF-α is mostly produced by Mφ in the synovial membrane and at the cartilage-pannus junction and possibly occupies a proximal position in the RA inflammatory cascade [39]. While an average of approximately 5% of synovial cells express TNF-α mRNA/protein in situ [40], the degree of TNF-α expression in the synovial tissue depends upon the prevailing histological configuration, resulting in different clinical variants [41]. Different disease stages and clinical variants are also reflected in serum and synovial fluid levels of TNF-α [42].

        The critical importance of TNF-α in RA is supported by several experimental observations: (a) TNF-α in combination with IL-1 is a potent inducer of synovitis [43], (b) transgenic, deregulated expression of TNF-α causes the development of chronic arthritis [44], (c) TNF-α is produced in synovial membrane and extra-articular/lymphoid organs in experimental arthritides, mimicking the systemic character of RA [2], (d) neutralization of TNF-α suppresses experimental arthritides [39, 43], and (e) administration of chimeric/humanized anti-TNF-α monoclonal antibodies or TNF-α receptor constructs has shown remarkable efficacy in acute disease and retardation of radiographic progression [3, 7, 11].

        As an interesting development, the analysis of gene expression in monocytes of anti-TNF-α-treated patients with RA may represent a powerful tool to identify regulation patterns applicable for diagnosis and therapy stratification or monitoring [45, 46] (Stuhlmuller B, Hernandez MM, Haeupl T, Kuban RJ, Gruetzkau A, Voss JW, Salfeld J, Kinne RW, Burmester GR, unpublished data). A reasonable expectation is that gene analyses also provide means to predict which patients are future responders to anti-TNF-α therapy.

        Tumor necrosis factor-alpha receptors

        TNF receptors are found in synovial tissue and fluid of patients with RA, especially in cases of severe disease [39]. There are two known TNF receptors, the R55 (TNF-R1) (high-affinity receptor) and the R75 (TNF-R2) (low-affinity receptor), which are expressed by both synovial Mφ and fibroblasts [47, 48]. The two TNF receptors can operate independently of one another, cooperatively, or by 'passing' TNF-α to one another [37], a complexity that may explain the tremendous sensitivity of target cells (such as Mφ) to minute concentrations of TNF-α. TNF receptors can also be shed, binding to soluble TNF-α and hence acting as natural inhibitors in disease. Recent studies have demonstrated that TNF-R1 may be primarily responsible for pro-inflammatory effects of TNF-α, whereas TNF-R2 may predominantly mediate anti-inflammatory effects of TNF-α [48] (reviewed in [49]). Thus, selective blockade of TNF-R1, instead of broad blockade of all effects of TNF-α, may become an attractive therapeutic approach [48, 50].


        In the RA synovial membrane, IL-1 is found predominantly in CD14+Mφ [51]; also, IL-1 levels in the synovial fluid significantly correlate with joint inflammation [52]. The two existing forms of IL-1 (IL-1α and IL-1β) show some differences (for example, low protein homology, stronger pro-inflammatory regulation of the IL-1β promoter, and secretion of inactive pro-IL-1β versus expression of membrane-bound IL-1α activity) but also strong similarities (that is, three-dimensional structures of the essential domains, molecular masses of pro-peptides, and mature-form processing proteases), resulting in almost identical binding capacity to the IL-1 receptors and comparable function. In arthritis, IL-1 appears to mediate a large part of the articular damage, as it profoundly influences proteoglycan synthesis and degradation [43, 53]. At the same time, IL-1 induces the production of MMP-1 and MMP-3 and enhances bone resorption; this is compatible with recent evidence from arthritis models and human RA suggesting that the tissue-destruction capacities of IL-1β may outweigh its genuine role in joint inflammation [53].

        Interleukin-1 receptors

        The IL-1 type I receptor (IL-1R1), which mediates cell activation via IL-1R accessory protein and IL-1 receptor-associated kinase (IRAK), is found on numerous cells in the synovial tissue of patients with RA [54]. In contrast, the type II receptor (IL-1R2) (also found in soluble form in serum), which lacks cell-activating properties and acts exclusively as a decoy receptor, is low in synovial tissue [55]. Similarly, IL-1RA, a soluble protein that blocks the action of IL-1 by binding to the type I receptor without receptor activation, has been detected only sporadically in RA synovial samples. In RA, the balance between IL-1 and its physiological inhibitor IL-1RA is therefore shifted in favor of IL-1, indicating a dysregulation crucial in promoting chronicity [53]. However, therapeutic application of IL-1RA (anakinra) appears to be only modestly effective in RA (reviewed in [56]). Therefore, it remains to be clarified whether the IL-1 pathway is a less suitable therapeutic target than TNF-α (for example, due to functional redundancy in the IL-1 receptor superfamily) or whether the biological molecule IL-1RA is suboptimal for therapy.


        IL-15, a cytokine of the IL-2 family with chemoattractant properties for memory T cells, is produced by lining layer cells (including Mφ) and is increased in RA synovial fluid [57]. Notably, peripheral or synovial T cells stimulated with IL-15 induce Mφ to produce IL-1β, TNF-α, IL-8, and monocyte chemotactic protein-1 [21, 57] but not the regulatory IL-10. Because IL-15 is also produced by Mφ themselves, this cytokine may (re)stimulate T cells, possibly self-perpetuating a pro-inflammatory loop [57]. The expression of IL-15 in the RA synovial membrane, its biological function, and its successful targeting in experimental arthritis have generated large expectations on the use of a fully humanized anti-IL-15 antibody in clinical trials [5658].


        In the RA synovial membrane, this cytokine of the IL-1 family is expressed in CD68+ Mφ contained in lymphoid aggregates. CD14+ Mφ of the RA synovial fluid also express the IL-18 receptor [59]. The pro-inflammatory role of IL-18 in arthritis (and its potential suitability as a therapeutic target in RA) is indicated by the following findings: (a) IL-18 treatment markedly aggravates experimental arthritis [59], (b) intra-articular overexpression of IL-18 induces experimental arthritis, (c) IL-18 is involved in the development of experimental streptococcal arthritis (a strongly Mφ-dependent model), (d) IL-18 is selectively overexpressed in the bone marrow of patients with juvenile idiopathic arthritis and Mφ activation syndrome [5], (e) IL-18 can stimulate osteoclast formation through upregulation of RANKL (receptor activator of NF-κB ligand) production by T cells in RA synovitis, and (f) IL-18 mediates its action via classic induction of TNF-α, GM-CSF, and interferon (IFN)-γ [59] or functional Toll-like receptors TLR-2 and TLR-4 in synovial cells [30] or else through the induction of synovial acute-phase serum amyloid proteins. The clinical relevance of synovial IL-18 is emphasised by its correlation with the systemic levels of C-reactive protein (CRP); also, IL-18 and CRP decrease in parallel in synovial tissue and serum following effective treatment with disease-modifying anti-rheumatic drugs [60]. In addition, peripheral blood mononuclear cells of RA patients show low levels of the IL-18 binding protein (a natural inhibitor of IL-18) and reduced sensitivity to stimulation with IL-12/IL-18, indicating profound dysregulation of the IL-18 system [61].


        The genuine role of IL-23, a cytokine of the IL-12 family predominantly produced by Mφ or dendritic cells, is unclear due to the sharing of the p40 subunit with IL-12 [62]. IL-23 has prominent pro-inflammatory functions, since transgenic expression in mice leads to multi-organ inflammation and premature death. IL-23 promotes various T-cell responses potentially relevant to RA [62]. Recent studies in experimental arthritis have demonstrated that mice lacking only IL-12 (p35-/-) show exacerbated arthritis, whereas mice lacking only IL-23 (p19-/-) are completely protected from arthritis [63]. In addition, activation of Mφ derived from arthritis-susceptible rats is paradoxically associated with reduced levels of pro-inflammatory mediators but high expression of IL-23 (p19), whereas non-susceptible rats show the inverse phenotype. If these findings were transferable to human RA, IL-23 would have a pro-inflammatory role and IL-12 a protective one. At the present time, it is unclear whether these findings fit into the recently introduced M1/M2 paradigm of differential Mφ activation [64, 65] and especially whether this paradigm can be exploited for a better understanding of the role of Mφ in RA.


        IL-27, another cytokine of the IL-12 family, is expressed by monocytes/Mφ following common inflammatory stimuli and displays a variety of pro- and anti-inflammatory properties [66]. In support of a pro-inflammatory role in arthritis, neutralizing antibodies against IL-27p28 suppress experimental arthritis [67].

        Chemokines and chemokine receptors

        Chemokines (subdivided into the CXC, CC, C, and CX3C families) are small proteins specialized in differential recruitment of leukocyte populations via a number of transmembrane receptors. Chemokines not only favor monocyte influx into inflamed tissue, but also play a key role in activation, functional polarization, and homing of patrolling monocytes/Mφ [65]. Notably, monocytes/Mφ express only select types of the numerous chemokine receptors (for example, CCR1, 2, 5, 7, and 8 as well as CX3CR1), representing a partially specific basis for prominent trafficking of monocyte/Mφ in arthritis. In RA, synovial Mφ produce several chemokines (for example, CCL3 [or Mφ inflammatory protein 1α], CCL5 [or RANTES], and CX3CL1 [or fractalkine]) and at the same time carry chemokine receptors, indicating the presence of autocrine loops in disease (reviewed in [68]). At the same time, chemokines are upregulated by the Mφ-derived TNF-α and IL-1. Significantly, some chemokines expressed in synovial Mφ (for example, IL-8 and fractalkine) are powerful promoters of angiogenesis, thus providing a link between Mφ activation and the prominent neo-vascularization of the RA synovium [69]. In RA, angiogenesis may be further promoted via activation of Mφ by advanced glycation end products, whereas thrombospondin-2 seems to downregulate angiogenesis. Because the enlargement of the vascular bed potentiates the influx of activated monocytes, down-modulation of the chemokine system represents a multi-potential target of anti-rheumatic therapy, as indicated by the promising results of treatment with a CCR1 antagonist in RA [68].

        Macrophage migration inhibitory factor

        One of the first ILs ever discovered, migration inhibitory factor (MIF), is an early-response cytokine abundantly released by Mφ. MIF stimulates a number of Mφ functions in an autocrine fashion (for example, secretion of TNF-α, phagocytosis, and generation of reactive oxygen species [ROS]). In addition, MIF confers resistance to apoptosis in Mφ and synovial fibroblasts, thus prolonging the survival of activated, disease-relevant cells. In RA, MIF is overexpressed in serum and synovial tissue in correlation with disease activity. Also, polymorphisms in the promoter or coding region of the human MIF gene are associated with features of juvenile idiopathic arthritis or adult RA [70].

        Monocyte/macrophage effector molecules with anti-inflammatory/regulatory effects in rheumatoid arthritis

        Mφ also produce anti-inflammatory cytokines, most notably IL-RA and IL-10, both cytokines engaged in autocrine regulatory loops (shown in the lower right quadrant of Figure 2) (Table 5).

        Interleukin-1 receptor antagonist

        Differentiated Mφ constitutively express IL-1RA, which is upregulated by pro-inflammatory mediators, including IL-1 itself or GM-CSF, and induces strong anti-inflammatory effects. By means of this feedback mechanism, Mφ therefore contribute to the termination of inflammatory reactions (reviewed in [71, 72]) (see above).


        IL-10, a Th2- and Mφ-derived cytokine with clear autocrine functions, reduces HLA-DR expression and antigen presentation in monocytes and inhibits the production of pro-inflammatory cytokines, GM-CSF, and Fc-γ receptors by synovial Mφ. Consistently with cytokine and chemokine downregulation, IL-10 clearly suppresses experimental arthritis. In spite of IL-10 elevation in serum and synovial compartments of patients with RA [73], some studies suggest a relative deficiency of IL-10 [74]. A combined IL-4/IL-10 deficiency probably tilts the cytokine balance to a pro-inflammatory predominance. In addition, the ex vivo production of IL-10 by RA peripheral blood mononuclear cells is negatively correlated with radiographic joint damage and progression of joint damage, suggesting that high IL-10 production is protective in RA. Similarly to IL-4, however, treatment with recombinant IL-10 does not improve RA. This may be partially explained by upregulation of the pro-inflammatory Fc-γ receptors I and IIA on monocytes/Mφ (reviewed in [2]).

        Monocyte/macrophage effector molecules with dual effects in rheumatoid arthritis

        Cytokines with a dual role are indicated in Tables 4 and 5.


        IL-6 is the most strikingly elevated cytokine in RA, especially in the synovial fluid during acute disease [75]. The acute rise is consistent with the role of IL-6 in acute-phase responses (Table 1). However, while IL-6 levels in the synovial fluid correlate with the degree of radiological joint damage, and IL-6 and soluble IL-6 receptors promote the generation of osteoclasts, this cytokine has phase-dependent effects; for example, it protects cartilage in acute disease but promotes excessive bone formation in chronic disease. While IL-6 is mostly produced by synovial fibroblasts and only partially by Mφ, two findings suggest that the striking IL-6 rise is a prominent outcome of Mφ activation: (a) the morphological vicinity of IL-6-expressing fibroblasts with CD14+ Mφ in the RA synovial tissue (reviewed in [2]) and (b) co-culture studies showing that IL-1 stimulates IL-6 production [17]. The role of IL-6 in experimental arthritis and the anti-arthritic effects of anti-IL-6 receptor antibodies suggest a role for anti-IL-6 therapy in RA [76] (reviewed in [77]).

        Transforming growth factor-beta

        In RA, Mφ express different transforming growth factor-beta (TGF-β) molecules and TGF-β receptors in the lining and sublining layers, at the cartilage-pannus junction, and in the synovial fluid [7880]. The pro-inflammatory effects of TGF-β are substantiated by induction of Mφ expression of Fc-γ receptor III (which elicits the release of tissue-damaging ROS) and promotion of monocyte adhesion and infiltration during chronic disease (reviewed in [80]). At the same time, TGF-β has anti-inflammatory properties; for example, it counteracts some IL-1 effects, including phagocytosis of collagen and possibly MMP production. A protective role of TGF-β in RA is also suggested by the association between TGF-β polymorphism and disease severity; that is, alleles associated with low TGF-β expression are correlated with stronger inflammation and poorer outcome [81]. Likewise, experimental arthritis is significantly ameliorated by activation of TGF-β via adenoviral expression of thrombospondin-1 [82]. The effects of TGF-β on tissue inhibitor of MMP (TIMP) are also unclear, as the regulation of MMP and TIMP may depend on different tissue domains (superficial versus deep cartilage layers) and may vary for intra- or extracellular digestion of collagen (reviewed in [2]).

        Treatment of human rheumatoid arthritis with conventional anti-macrophage approaches

        The role of Mφ-derived cytokines in the perpetuation of RA, the pathophysiological dichotomy between joint inflammation and cartilage destruction, and the crucial significance of activated synovial Mφ in relation to permanent joint damage [1] have led to a radical re-evaluation of the conventional anti-inflammatory and disease-modifying treatments in relation to Mφ parameters in order to potentiate therapeutic effects (for example, via combination approaches [83]) and reduce side effects. For anti-Mφ effects of conventional anti-rheumatic therapy in RA (including methotrexate, leflunomide, anti-malarials, gold compounds, corticosteroids, and non-steroidal anti-inflammatory drugs), the reader is referred to a recent comprehensive review [11]. Recent findings show that conventional and specific anti-rheumatic treatments predominantly target sublining rather than lining Mφ; also, different therapeutic approaches seem to result in similar histological changes in the inflamed synovial membrane, including significant reduction of sublining Mφ. This, in turn, is significantly correlated with the degree of clinical improvement [11, 12]. Thus, different pathogenetic mechanisms may funnel into similar disease pathway(s), leading to massive activation of Mφ and providing the rationale for targeted anti-Mφ therapy.

        Non-conventional and experimental anti-macrophage therapy

        Counteraction of monocyte/macrophage activation at a cellular level

        Apoptosis-inducing agents

        Physical elimination of disease-relevant cells (for example, activated Mφ or osteoclasts) by apoptosis is advantageous because it circumvents secondary tissue damage by restraining cellular organelles in apoptotic vesicles. Phagocytic incorporation of liposome-encapsulated non-amino-bisphosphonates by activated monocytes, for example, induces apoptosis in these cells [84] (Figure 3). Systemic application of encapsulated bisphosphonates in experimental arthritis not only counteracts joint swelling, but also prevents local joint destruction and subchondral bone damage [85]; in addition, it shows protective effects on remote bone damage. Studies in RA show that a single intra-articular administration of clodronate liposomes leads to Mφ depletion and decreased expression of adhesion molecules in the lining layer of RA synovial tissue [86]. Selective targeting of activated Mφ has also been demonstrated using either apoptosis-inducing immunotoxins coupled to anti-Fc-γ receptor I (CD64) antibodies or folate receptor-mediated targeting (reviewed in [2]). In general, liposome encapsulation can also be exploited for selective delivery of Mφ-modulating drugs [87] (reviewed in [2]) or gene therapy constructs (reviewed in [88]).
        Figure 3

        Potential and established approaches for modulation of monocyte/macrophage (Mφ) functions in rheumatoid arthritis. COX-2, cyclooxygenase-2; EC, endothelial cells; FB, fibroblasts; ICAM-1, intracellular adhesion molecule-1; IFN-β, interferon-beta; IL, interleukin; IL-1RA, interleukin-1 receptor antagonist; iNOS, inducible nitric-oxide synthase; mAbs, mononuclear antibodies; cPLA2, cytosolic phospholipase A2; MMP, metalloprotease; MTX, methotrexate; NF-κB, nuclear factor-kappa-B; PGE2, prostaglandin E2; PPAR-γ, peroxisome proliferator-activated receptor-gamma; ROS, reactive oxygen species; TNF-α, tumor necrosis factor-alpha. Reproduced with permission from Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55–75 [2].

        Control of gene transcription

        The transcription of most cytokine genes in monocytes/Mφ depends on the activation of NF-κB and NF-κM transcription factors or that of the activator protein-1 (AP-1) complex. In RA synovial Mφ, the expression of NF-κB is more pronounced than that of AP-1, a selectivity that may bear important therapeutic implications [89]. Accordingly, the anti-arthritic effects of IL-4 may be based on the selective suppression of NF-κB in Mφ. IL-10 also downregulates the production of pro-inflammatory monokines, inhibiting the nuclear factors NF-κB, AP-1, or NF-IL-6. Unlike IL-4, IL-10 can also enhance degradation of the mRNA for IL-1 and TNF-α (reviewed in [2]). In general, therefore, targeted inhibition of 'pro-inflammatory' signal transduction pathways in Mφ represents an attractive therapeutic approach [90].

        Gene therapy in experimental arthritis

        Gene therapy has been applied in experimental arthritis models to counteract Mφ-derived IL-1 and TNF-α or to deliver/overexpress protective IL-1RA, soluble IL-1 type I receptor-IgG fusion protein, and type I soluble TNF-α receptor-IgG fusion protein. This has been extended to (Mφ-derived) anti-inflammatory cytokines (that is, IL-4, IL-10, IL-13, IFN-β, or TGF-β) and to 'molecular synovectomy' (either by expression of herpes simplex virus-thymidine kinase with subsequent administration of ganciclovir or by overexpression of Fas-ligand/inhibitors of nuclear translocation of NF-κB, resulting in synovial cell apoptosis [88, 91, 92]). Therefore, gene therapy aimed at neutralizing pro-inflammatory Mφ products, overexpressing Mφ-regulating mediators, or simply eliminating overly activated Mφ remains promising for the treatment of arthritis.


        The multitude and abundance of Mφ-derived mediators in RA and their paracrine and autocrine effects (including those directed to other cells of the myeloid lineage) indicate that Mφ are local and systemic amplifiers of disease severity and perpetuation. The main local mechanisms include (a) self-perpetuating chemokine-mediated recruitment of inflammatory cells, (b) cytokine-mediated activation of newly immigrated inflammatory cells, (c) cell contact-mediated activation of neighboring inflammatory cells, (d) cytokine- and cell contact-mediated secretion of matrix-degrading enzymes, (e) activation of mature dendritic cells and cytokine-mediated differentiation of Mφ (and possibly B cells, T cells, and mesenchymal cells) into antigen-presenting cells, with possible effects on spreading of autoimmunity to cryptic epitopes, (f) neo-vascularization, with potentiation of cellular and exudatory mechanisms, and (g) (trans)differentiation of Mφ into osteoclasts involved in subchondral bone damage. At a systemic level, amplification of disease can proceed at least through the following mechanisms: (a) acute-phase response network, (b) systemic production of TNF-α, (c) anomalies in bone marrow differentiation, and (d) chronic activation of circulating monocytes.

        Although uncovering the etiology of disease remains the ultimate goal of research, the efforts in understanding how activated Mφ influence disease have led to optimization strategies to selectively target activated Mφ in RA (Figure 3). This approach has at least two advantages: (a) striking the very cell population that mediates/amplifies most of the irreversible cartilage destruction and (b) minimizing adverse effects on other cells that may have no (or marginal) effects on joint damage.



        activator protein-1


        C-reactive protein


        granulocyte macrophage colony-stimulating factor






        interleukin-1 receptor antagonist






        migration inhibitory factor




        mononuclear phagocyte system


        nuclear factor


        pattern-recognition receptor


        rheumatoid arthritis


        reactive oxygen species


        staphylococcal enterotoxin B


        transforming growth factor-beta


        tissue inhibitor of metalloprotease


        Toll-like receptor


        tumor necrosis factor


        tumor necrosis factor receptor 1


        tumor necrosis factor receptor 2



        Ernesta Palombo-Kinne is gratefully acknowledged for critical revision of the manuscript. This study was supported by the German Federal Ministry of Education and Research (BMBF) (grants FKZ 01ZZ9602, 01ZZ0105, and 010405 to RWK), the Interdisciplinary Center for Clinical Research (IZKF) Jena, including grants for junior researchers, (grants FKZ 0312704B and 0313652B to RWK), the Jena Centre for Bioinformatics; (grant 01GS0413, NGFN-2 to RWK); the German Research Foundation (DFG) (grants KI 439/7-1/3 and KI 439/6-1/3 to RWK); the Thuringian Ministry of Science, Research, and Art (FKZ B 311-00026); and a grant for the advancement of female scientists (LUBOM Thuringia).

        Authors’ Affiliations

        Experimental Rheumatology Unit, Department of Orthopedics, University Clinic
        Department of Rheumatology and Clinical Immunology, Charité University Hospital, Humboldt University of Berlin


        1. Mulherin D, Fitzgerald O, Bresnihan B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996, 39:115–124.PubMedView Article
        2. Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in rheumatoid arthritis. In Rheumatoid Arthritis. Edited by: Firestein GS, Panayi GS, Wollheim FA. New York: Oxford University Press; 2006:55–75.
        3. Smolen JS, Steiner G: Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003, 2:473–488.PubMedView Article
        4. Stuhlmüller B, Ungethüm U, Scholze S, Martinez L, Backhaus M, Kraetsch HG, Kinne RW, Burmester GR: Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis. Arthritis Rheum 2000, 43:775–790.PubMedView Article
        5. Maeno N, Takei S, Imanaka H, Yamamoto K, Kuriwaki K, Kawano Y, Oda H: Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum 2004, 50:1935–1938.PubMedView Article
        6. Lavagno L, Gunella G, Bardelli C, Spina S, Fresu LG, Viano I, Brunelleschi S: Anti-inflammatory drugs and tumor necrosis factor-alpha production from monocytes: role of transcription factor NF-kappaB and implication for rheumatoid arthritis therapy. Eur J Pharmacol 2004, 501:199–208.PubMedView Article
        7. Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN: Anti-TNF therapy: where have we got to in 2005? J Autoimmun 2005,25(Suppl):26–28.PubMedView Article
        8. van Rooijen N, Kesteren-Hendrikx E: ' In vivo ' depletion of macrophages by liposome-mediated 'suicide'. Methods Enzymol 2003, 373:3–16.PubMedView Article
        9. Sweeney SE, Firestein GS: Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol 2004, 16:231–237.PubMedView Article
        10. Westra J, Doornbos-van der Meer B, de Boer P, van Leeuwen MA, van Rijswijk MH, Limburg PC: Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Arthritis Res Ther 2004, 6:R384-R392.PubMedView Article
        11. Franz JK, Burmester GR: The needle and the damage done. Ann Rheum Dis 2005, 64:798–800.PubMedView Article
        12. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, McInnes IB, Bresnihan B, Tak PP: Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005, 64:834–838.PubMedView Article
        13. Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953–964.PubMedView Article
        14. Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957–2963.PubMedView Article
        15. Monaco C, Andreakos E, Kiriakidis S, Feldmann M, Paleolog E: T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy 2004, 3:35–42.PubMedView Article
        16. Kinne RW, Stuhlmuller B, Palombo-Kinne E, Burmester GR: The role of macrophages in the pathogenesis of rheumatoid arthritis. In Rheumatoid Arthritis: The New Frontiers in Pathogenesis and Treatment. Edited by: Wollheim F, Firestein GS, Panayi GS. Oxford: Oxford University Press; 2000:69–87.
        17. Chomarat P, Rissoan MC, Pin JJ, Banchereau J, Miossec P: Contribution of IL-1, CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-synoviocyte interactions. J Immunol 1995, 155:3645–3652.PubMed
        18. Scott BB, Weisbrot LM, Greenwood JD, Bogoch ER, Paige CJ, Keystone EC: Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation. Arthritis Rheum 1997, 40:490–498.PubMedView Article
        19. McInnes IB, Leung BP, Liew FY: Cell-cell interactions in synovitis: Interactions between T lymphocytes and synovial cells. Arthritis Res 2000, 2:374–378.PubMedView Article
        20. Burger D, Dayer JM: The role of human T-lymphocyte-monocyte contact in inflammation and tissue destruction. Arthritis Res 2002, 4:S169-S176.PubMedView Article
        21. Sebbag M, Parry SL, Brennan FM, Feldmann M: Cytokine stimulation of T lymphocytes regulates their capacity to induce monocyte production of tumor necrosis factor-alpha, but not interleukin-10: possible relevance to pathophysiology of rheumatoid arthritis. Eur J Immunol 1997, 27:624–632.PubMedView Article
        22. Tran CN, Lundy SK, Fox DA: Synovial biology and T cells in rheumatoid arthritis. Pathophysiology 2005, 12:183–189.PubMedView Article
        23. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF: CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol 2004, 173:6418–6426.PubMed
        24. Miossec P: An update on the cytokine network in rheumatoid arthritis. Curr Opin Rheumatol 2004, 16:218–222.PubMedView Article
        25. Lundy SK, Sarkar S, Tesmer LA, Fox DA: Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther 2007, 9:202.PubMedView Article
        26. Giles JT, Bathon JM: Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004, 19:320–334.PubMedView Article
        27. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN: The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006, 33:2398–2408.PubMed
        28. Hopkins PA, Fraser JD, Pridmore AC, Russell HH, Read RC, Sriskandan S: Superantigen recognition by HLA class II on monocytes up-regulates toll-like receptor 4 and enhances proinflammatory responses to endotoxin. Blood 2005, 105:3655–3662.PubMedView Article
        29. Seibl R, Kyburz D, Lauener RP, Gay S: Pattern recognition receptors and their involvement in the pathogenesis of arthritis. Curr Opin Rheumatol 2004, 16:411–418.PubMedView Article
        30. Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U, Hantzschel H, Michel BA, Gay RE, Gay S, et al.: Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004, 172:1256–1265.PubMed
        31. Frasnelli ME, Tarussio D, Chobaz-Peclat V, Busso N, So A: TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res Ther 2005, 7:R370-R379.PubMedView Article
        32. Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, Yoshikawa H, Nagata S: Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006, 443:998–1002.PubMedView Article
        33. Cutolo M, Lahita RG: Estrogens and arthritis. Rheum Dis Clin North Am 2005, 31:19–27.PubMedView Article
        34. Keith JC, Albert LM, Leathurby Y, Follettie M, Wang L, Borges-Marcucci L, Chadwick CC, Steffan RJ, Harnish DC: The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kB transcriptional activity in models of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R427-R438.PubMedView Article
        35. Taylor PC: Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Des 2003, 9:1095–1106.PubMedView Article
        36. Wong PK, Campbell IK, Robb L, Wicks IP: Endogenous IL-11 is pro-inflammatory in acute methylated bovine serum albumin/interleukin-1-induced (mBSA/IL-1)arthritis. Cytokine 2005, 29:72–76.PubMedView Article
        37. Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al.: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995, 83:793–802.PubMedView Article
        38. Georgopoulos S, Plows D, Kollias G: Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 1996, 46:86–97.PubMed
        39. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397–440.PubMedView Article
        40. Firestein GS, Alvaro-Gracia JM, Maki R, Alvaro-Garcia JM: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990, 144:3347–3353.PubMed
        41. Klimiuk PA, Goronzy JJ, Björ nsson J, Beckenbaugh RD, Weyand CM: Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997, 151:1311–1319.PubMed
        42. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J: Serum cytokines in different histological variants of rheumatoid arthritis. J Rheumatol 2001, 28:1211–1217.PubMed
        43. van den Berg WB, Joosten LA, Kollias G, Van De Loo FA: Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction. Ann Rheum Dis 1999, 58:I40-I48.PubMedView Article
        44. Kollias G: Modeling the function of tumor necrosis factor in immune pathophysiology. Autoimmun Rev 2004, 3:S24-S25.PubMed
        45. Toh ML, Marotte H, Blond JL, Jhumka U, Eljaafari A, Mougin B, Miossec P: Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. Arthritis Rheum 2006, 54:2109–2118.PubMedView Article
        46. Lequerré T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, Vittecoq O, Daveau M, Mejjad O, Daragon A, Tron F, et al.: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R105.PubMedView Article
        47. Alsalameh S, Winter K, Al-Ward R, Wendler J, Kalden JR, Kinne RW: Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scand J Immunol 1999, 49:278–285.PubMedView Article
        48. Kunisch E, Gandesiri M, Fuhrmann R, Roth A, Winter R, Kinne RW: Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF-alpha in early-passage synovial fibroblasts via tumor necrosis factor receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1043–1051.PubMedView Article
        49. Alsalameh S, Amin RJ, Kunisch E, Jasin HE, Kinne RW: Preferential induction of prodestructive matrix metalloproteinase-1 and proinflammatory interleukin 6 and prostaglandin E2 in rheumatoid arthritis synovial fibroblasts via tumor necrosis factor receptor-55. J Rheumatol 2003, 30:1680–1690.PubMed
        50. Deng GM, Zheng L, Chan FK, Lenardo M: Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 2005, 11:1066–1072.PubMedView Article
        51. Wood NC, Dickens E, Symons JA, Duff GW: In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clin Immunol Immunopathol 1992, 62:295–300.PubMedView Article
        52. Arend WP, Malyak M, Guthridge CJ, Gabay C: Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998, 16:27–55.PubMedView Article
        53. Dinarello CA: The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002, 20:S1-S13.PubMed
        54. Deleuran BW, Chu CQ, Field M, Brennan FM, Katsikis P, Feldmann M, Maini RN: Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. Br J Rheumatol 1992, 31:801–809.PubMedView Article
        55. Silvestri T, Pulsatelli L, Dolzani P, Frizziero L, Facchini A, Meliconi R: In vivo expression of inflammatory cytokine receptors in the joint compartments of patients with arthritis. Rheumatol Int 2006, 26:360–368.PubMedView Article
        56. McInnes IB, Liew FY: Cytokine networks-towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 2005, 1:31–39.PubMedView Article
        57. McInnes IB, Gracie JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:392–397.PubMedView Article
        58. Connell L, McInnes IB: New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2006, 20:865–878.PubMedView Article
        59. Gracie JA: Interleukin-18 as a potential target in inflammatory arthritis. Clin Exp Immunol 2004, 136:402–404.PubMedView Article
        60. Rooney T, Murphy E, Benito M, Roux-Lombard P, FitzGerald O, Dayer JM, Bresnihan B: Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis 2004, 63:1393–1398.PubMedView Article
        61. Dinarello CA: Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007, 27:98–114.PubMedView Article
        62. Vandenbroeck K, Alloza I, Gadina M, Matthys P: Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol 2004, 56:145–160.PubMedView Article
        63. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ: Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951–1957.PubMedView Article
        64. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000, 164:6166–6173.PubMed
        65. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677–686.PubMedView Article
        66. Villarino AV, Hunter CA: Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res Ther 2004, 6:225–233.PubMedView Article
        67. Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N: Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol 2004, 173:1171–1178.PubMed
        68. Haringman JJ, Kraan MC, Smeets TJ, Zwinderman KH, Tak PP: Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:715–721.PubMedView Article
        69. Koch AE: Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003, 62:ii60-ii67.PubMedView Article
        70. Morand EF, Leech M: Macrophage migration inhibitory factor in rheumatoid arthritis. Front Biosci 2005, 10:12–22.PubMedView Article
        71. Bresnihan B: Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives. Clin Exp Rheumatol 2002, 20:S32-S34.PubMed
        72. Dinarello CA: Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 2004, 4:378–385.PubMedView Article
        73. Isomaki P, Luukkainen R, Saario R, Toivanen P, Punnonen J: Interleukin-10 functions as an antiinflammatory cytokine in rheumatoid synovium. Arthritis Rheum 1996, 39:386–395.PubMedView Article
        74. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M: Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994, 179:1517–1527.PubMedView Article
        75. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988, 31:784–788.PubMedView Article
        76. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54:2817–2829.PubMedView Article
        77. Smolen JS, Maini RN: Interleukin-6: a new therapeutic target. Arthritis Res Ther 2006,8(Suppl 2):S5.PubMedView Article
        78. Chu CQ, Field M, Abney E, Zheng RQ, Allard S, Feldmann M, Maini RN: Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 1991, 86:380–386.PubMedView Article
        79. Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ, Rayan G, Koch AE: Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 1995, 76:187–194.PubMedView Article
        80. Chen W, Wahl SM: TGF-beta: receptors, signaling pathways and autoimmunity. Curr Dir Autoimmun 2002, 5:62–91.PubMedView Article
        81. Mattey DL, Nixon N, Dawes PT, Kerr J: Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis. Ann Rheum Dis 2005, 64:1190–1194.PubMedView Article
        82. Jou IM, Shiau AL, Chen SY, Wang CR, Shieh DB, Tsai CS, Wu CL: Thrombospondin 1 as an effective gene therapeutic strategy in collagen-induced arthritis. Arthritis Rheum 2005, 52:339–344.PubMedView Article
        83. Cronstein BN: Therapeutic cocktails for rheumatoid arthritis: the mixmaster's guide. Arthritis Rheum 2004, 50:2041–2043.PubMedView Article
        84. Schmidt-Weber CB, Rittig M, Buchner E, Hauser I, Schmidt I, Palombo-Kinne E, Emmrich F, Kinne RW: Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes. J Leukoc Biol 1996, 60:230–244.PubMed
        85. Kinne RW, Schmidt-Weber CB, Hoppe R, Buchner E, Palombo-Kinne E, Nürnberg E, Emmrich F: Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 1995, 38:1777–1790.PubMedView Article
        86. Barrera P, Blom A, van Lent PL, van Bloois L, Beijnen JH, van Rooijen N, de Waal Malefijt MC, van de Putte LB, Storm G, van den Berg WB: Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum 2000, 43:1951–1959.PubMedView Article
        87. Metselaar JM, van den Berg WB, Holthuysen AE, Wauben MH, Storm G, van Lent PL: Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis 2004, 63:348–353.PubMedView Article
        88. Evans CH, Ghivizzani SC, Lechman ER: Lessons learned from gene transfer approaches. Arthritis Res 1999, 1:21–24.PubMedView Article
        89. Handel ML, Girgis L: Transcription factors. Best Pract Res Clin Rheumatol 2001, 15:657–675.PubMedView Article
        90. Firestein GS: Holy Grail for rheumatoid arthritis? Arthritis Rheum 2004, 50:2381–2386.PubMedView Article
        91. Boissier MC, Bessis N: Therapeutic gene transfer for rheumatoid arthritis. Reumatismo 2004, 56:51–61.PubMed
        92. Huber LC, Pap T, Muller-Ladner U, Gay RE, Gay S: Gene targeting: roadmap to future therapies. Curr Rheumatol Rep 2004, 6:323–325.PubMedView Article
        93. Mueller RB, Skapenko A, Grunke M, Wendler J, Stuhlmuller B, Kalden JR, Schulze-Koops H: Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis Rheum 2005, 52:451–460.PubMedView Article
        94. Brinckerhoff CE, Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002, 3:207–214.PubMedView Article
        95. Wang X, Liang J, Koike T, Sun H, Ichikawa T, Kitajima S, Morimoto M, Shikama H, Watanabe T, Sasaguri Y, et al.: Overexpression of human matrix metalloproteinase-12 enhances the development of inflammatory arthritis in transgenic rabbits. Am J Pathol 2004, 165:1375–1383.PubMed
        96. Heller RA, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J, Woolley DE, Davis RW: Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA 1997, 94:2150–2155.PubMedView Article
        97. O'Hara R, Murphy EP, Whitehead AS, Fitzgerald O, Bresnihan B: Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 2004, 50:1788–1799.PubMedView Article
        98. Hahn G, Stuhlmuller B, Hain N, Kalden JR, Pfizenmaier K, Burmester GR: Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J Clin Invest 1993, 91:862–870.PubMedView Article
        99. Hamerlinck FF: Neopterin: a review. Exp Dermatol 1999, 8:167–176.PubMedView Article
        100. Rosengren S, Hoffman H, Bugbee W, Boyle DL: Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann Rheum Dis 2005, 64:708–714.PubMedView Article
        101. Van Roon JA, Bijlsma JW, van De Winkel JG, Lafeber FP: Depletion of synovial macrophages in rheumatoid arthritis by an anti-Fc{gamma}RI-Calicheamicin immunoconjugate. Ann Rheum Dis 2005, 64:865–870.PubMedView Article
        102. Wijngaarden S, van De Winkel JG, Jacobs KM, Bijlsma JW, Lafeber FP, Van Roon JA: A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Arthritis Rheum 2004, 50:3878–3887.PubMedView Article
        103. Liu H, Pope RM: Phagocytes: mechanisms of inflammation and tissue destruction. Rheum Dis Clin North Am 2004, 30:19–39.PubMedView Article
        104. Dao DN, Kremer L, Guerardel Y, Molano A, Jacobs WR Jr, Porcelli SA, Briken V: Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12 production in macrophages. Infect Immun 2004, 72:2067–2074.PubMedView Article
        105. Briken V, Porcelli SA, Besra GS, Kremer L: Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol Microbiol 2004, 53:391–403.PubMedView Article
        106. Mogensen TH, Paludan SR: Reading the viral signature by Toll-like receptors and other pattern recognition receptors. J Mol Med 2005, 83:180–192.PubMedView Article
        107. Itescu S: Rheumatic aspects of acquired immunodeficiency syndrome. Curr Opin Rheumatol 1996, 8:346–353.PubMedView Article
        108. Cheevers WP, Snekvik KR, Trujillo JD, Kumpula-McWhirter NM, Pretty On Top KJ, Knowles DP: Prime-boost vaccination with plasmid DNA encoding caprine-arthritis encephalitis lentivirus env and viral SU suppresses challenge virus and development of arthritis. Virology 2003, 306:116–125.PubMedView Article
        109. Iguchi T, Kurosaka M, Ziff M: Electron microscopic study of HLA-DR and monocyte/macrophage staining cells in the rheumatoid synovial membrane. Arthritis Rheum 1986, 29:600–613.PubMedView Article
        110. Bresnihan B, Gogarty M, Fitzgerald O, Dayer JM, Burger D: Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production? Arthritis Res Ther 2004, 6:R563-R566.View Article
        111. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, et al.: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479–490.PubMedView Article
        112. Chen Q, Carroll HP, Gadina M: The newest interleukins: recent additions to the ever-growing cytokine family. Vitam Horm 2006, 74:207–228.PubMedView Article
        113. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo . Proc Natl Acad Sci USA 2007, 104:282–287.PubMedView Article
        114. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA: Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005, 22:131–142.PubMed
        115. Brennan F, Beech J: Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007, 19:296–301.PubMedView Article
        116. Van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP: Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:113–119.PubMedView Article
        117. Leonard WJ: Interleukin-7 deficiency in rheumatoid arthritis. Arthritis Res Ther 2005, 7:42–43.PubMedView Article
        118. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN: IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 2003, 100:125–130.PubMedView Article
        119. Jüngel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, Michel BA, Gay RE, Emmrich F, Gay S, et al.: Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:1468–1476.PubMedView Article
        120. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, et al.: Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004, 5:752–760.PubMedView Article
        121. Wong PK, Campbell IK, Egan PJ, Ernst M, Wicks IP: The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum 2003, 48:1177–1189.PubMedView Article
        122. Romer J, Hasselager E, Norby PL, Steiniche T, Thorn CJ, Kragballe K: Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J Invest Dermatol 2003, 121:1306–1311.PubMedView Article
        123. Liao SC, Cheng YC, Wang YC, Wang CW, Yang SM, Yu CK, Shieh CC, Cheng KC, Lee MF, Chiang SR, et al.: IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol 2004, 173:6712–6718.PubMed
        124. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, Brandt C, Jelinek L, Madden K, McKernan PA, et al.: Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002, 277:47517–47523.PubMedView Article
        125. Wolk K, Kunz S, Asadullah K, Sabat R: Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002, 168:5397–5402.PubMed
        126. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R: IL-22 increases the innate immunity of tissues. Immunity 2004, 21:241–254.PubMedView Article
        127. Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, Grimm EA: The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002, 168:6041–6046.PubMed
        128. Vandenbroeck K, Cunningham S, Goris A, Alloza I, Heggarty S, Graham C, Bell A, Rooney M: Polymorphisms in the interferon-gamma/interleukin-26 gene region contribute to sex bias in susceptibility to rheumatoid arthritis. Arthritis Rheum 2003, 48:2773–2778.PubMedView Article
        129. Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, Joosten LA, van den Berg WB: Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004, 50:3856–3865.PubMedView Article
        130. Siren J, Pirhonen J, Julkunen I, Matikainen S: IFN-{alpha} Regulates TLR-Dependent Gene Expression of IFN-{alpha}, IFN-{beta}, IL-28, and IL-29. J Immunol 2005, 174:1932–1937.PubMed
        131. Miossec P, Naviliat M, Dupuy d'Angeac A, Sany J, Banchereau J: Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum 1990, 33:1180–1187.PubMedView Article
        132. Allen JB, Wong HL, Costa GL, Bienkowski MJ, Wahl SM: Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 1993, 151:4344–4351.PubMed
        133. Van Roon JA, Lafeber FP, Bijlsma JW: Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001, 44:3–12.PubMedView Article
        134. Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM: Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum 1998, 41:1388–1397.PubMedView Article
        135. Klimiuk PA, Goronzy JJ, Weyand CM: IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol 1999, 162:4293–4299.PubMed
        136. Blaschke S, Schulz H, Schwarz G, Blaschke V, Muller GA, Reuss-Borst M: Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol 2001, 28:12–21.PubMed
        137. Kaufmann J, Franke S, Kientsch-Engel R, Oelzner P, Hein G, Stein G: Correlation of circulating interleukin 16 with proinflammatory cytokines in patients with rheumatoid arthritis. Rheumatology (Oxford) 2001, 40:474–475.View Article
        138. Lard LR, Roep BO, Toes RE, Huizinga TW: Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis. J Rheumatol 2004, 31:35–39.PubMed
        139. Tak PP: IFN-beta in rheumatoid arthritis. Front Biosci 2004, 9:3242–3247.PubMedView Article
        140. Mi Z, Ghivizzani SC, Lechman E, Glorioso JC, Evans CH, Robbins PD: Adverse effects of adenovirus-mediated gene transfer of human transforming growth factor beta 1 into rabbit knees. Arthritis Res Ther 2003, 5:R132-R139.PubMedView Article


        © BioMed Central Ltd 2007